臨床血液
Online ISSN : 1882-0824
Print ISSN : 0485-1439
ISSN-L : 0485-1439
短報
Daratumumab/bortezomib/dexamethasone療法中にListeria髄膜炎を発症した多発性骨髄腫
藤井 知紀大野 伸広北原 信介小林 誠一郎佐原 直日松永 貴志
著者情報
ジャーナル 認証あり

2022 年 63 巻 2 号 p. 117-120

詳細
抄録

An 88-year-old woman was diagnosed with multiple myeloma received third-line chemotherapy, including DBd (daratumumab [DARA], bortezomib, and dexamethasone [Dex]), and the myeloma was in remission. Sulfamethoxazole/trimethoprim (ST) prophylaxis was discontinued because the dose of Dex was reduced to 20 mg every 4 weeks after 21 cycles of DBd. After 28 cycles of DBd, altered consciousness with fever ensued, and she was referred to the emergency department where Listeria monocytogenes (LM) meningitis was diagnosed. CD38 inactivation is associated with increased LM susceptibility. In patients on Dara-based chemotherapy, antibiotic prophylaxis should be considered using ST, which has activity against Listeria.

著者関連情報
© 2022 一般社団法人 日本血液学会
前の記事 次の記事
feedback
Top